Affimer's12 Nov 2020 09:21
The one very important thing the Chinese dont have access to!
https://avacta.com/therapeutics/affimer-technology/
From the presentation:
On BAMS
- Highly sensitive detection of the S1 spike protein of
SARS-CoV-2 from as little as one bead.
- Exquisite specificity endowed by Affimer capture
combined with mass spectrum fingerprint.
On stem cell treatments:
Expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620) and AffyXell
Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments
incorporating Avacta's neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also
prepare to rapidly develop similar therapies for future global pandemics.
On waste water testing:
Collaboration with Integumen plc (AIM: SKIN) ("Integumen") to evaluate recently generated Affimer reagents that bind the
SARS-CoV-2 spike protein for the detection of the coronavirus in waste water, to provide a real-time alert system to warn of
localised COVID-19 outbreaks
On ELISA test:
Data acquired at Liverpool School of Tropical Medicine show that the
ELISA test detects the presence of spike protein from live virus in
saliva samples with as little as a few thousand virus particles per ml
which is at the lower end of the infectious range
On OEM deals:
OEM deals have the potential to expand the commercial opportunity for Avacta
Significant additional third party commercial interest in spike protein Affimer binders (including several global
IVD companies, bioprocessing companies and research reagents suppliers).
On production:
Avacta is expanding its in-house Affimer production facilities and putting in place very
large scale contract manufacturing partners; Affimer supply will not be a limiting factor
and nor will nitrocellulose strip
Sign In
Follow the stocks
